RecruitingNot ApplicableNCT04856059
Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI
Sponsor
University Health Network, Toronto
Enrollment
300 participants
Start Date
Jun 15, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Fabry disease;
- Age ≥ 18 years.
Exclusion Criteria2
- History of myocardial infarction;
- Contraindication to MRI.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTCardiac MRI, ECG/Holter and Blood Biomarkers
Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04856059
Related Trials
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742283 locations
A Study of Patients With Fabry Disease (US Specific)
NCT069063678 locations
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
NCT0690426111 locations
T1 Mapping in Fabry Disease
NCT059237882 locations
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
NCT069410255 locations